Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
34
WST Quote, Financials, Valuation and Earnings
Last price:
$211.05
Seasonality move
:
2.69%
Day range:
$206.10 - $211.23
52-week range:
$187.43 - $352.33
Dividend yield:
0.39%
P/E ratio:
33.10x
P/S ratio:
5.34x
P/B ratio:
5.65x
Volume:
879.6K
Avg. volume:
825.8K
1-year change:
-35.94%
Market cap:
$15.1B
Revenue:
$2.9B
EPS (TTM):
$6.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$687.4M | $1.26 | 3.28% | -0.47% | $281.92 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 6.07% | 68.64% | $140.57 |
|
PDEX
Pro-Dex
|
$17.7M | $0.47 | 19.14% | 4.44% | $56.00 |
|
TFX
Teleflex
|
$699.4M | $2.88 | 2.91% | 98.97% | $157.62 |
|
TMCI
Treace Medical Concepts
|
$52.1M | -$0.30 | 5.9% | -21.86% | $9.73 |
|
UFPT
UFP Technologies
|
$139.9M | $2.01 | 37.56% | 28.57% | $311.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$210.85 | $281.92 | $15.1B | 33.10x | $0.21 | 0.39% | 5.34x |
|
ABT
Abbott Laboratories
|
$133.58 | $140.57 | $232.4B | 17.33x | $0.59 | 1.71% | 5.51x |
|
PDEX
Pro-Dex
|
$40.38 | $56.00 | $131.7M | 14.47x | $0.00 | 0% | 2.12x |
|
TFX
Teleflex
|
$122.27 | $157.62 | $5.4B | 38.57x | $0.34 | 1.11% | 1.90x |
|
TMCI
Treace Medical Concepts
|
$5.74 | $9.73 | $361.1M | -- | $0.00 | 0% | 1.70x |
|
UFPT
UFP Technologies
|
$234.20 | $311.00 | $1.8B | 28.67x | $0.00 | 0% | 3.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 1.022 | 1.26% | 1.80x |
|
ABT
Abbott Laboratories
|
21.34% | 0.731 | 6.18% | 1.27x |
|
PDEX
Pro-Dex
|
34.14% | -1.377 | 11.31% | 1.41x |
|
TFX
Teleflex
|
31.78% | 0.357 | 30.89% | 1.11x |
|
TMCI
Treace Medical Concepts
|
33.65% | 4.109 | 10.12% | 3.23x |
|
UFPT
UFP Technologies
|
33.63% | 3.172 | 11.76% | 1.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$231.9M | $127.6M | 16.23% | 17.47% | 15.89% | $58.1M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.7B | 23.5% | 31.31% | 18.43% | $933M |
|
PDEX
Pro-Dex
|
$5.8M | $3.6M | 20.23% | 29.31% | 27.56% | $574K |
|
TFX
Teleflex
|
$389.4M | $130.3M | 2.43% | 3.41% | 18.2% | $43.1M |
|
TMCI
Treace Medical Concepts
|
$41.9M | -$15.6M | -32% | -47.17% | -27.79% | $655K |
|
UFPT
UFP Technologies
|
$42.2M | $23.4M | 13.85% | 19.38% | 15.59% | $11M |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or ABT?
Abbott Laboratories has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 12.79%. West Pharmaceutical Services's return on equity of 17.47% beat Abbott Laboratories's return on equity of 31.31%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B ABTAbbott Laboratories56.86% $0.76 $62.3B -
What do Analysts Say About WST or ABT?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 33.71%. On the other hand Abbott Laboratories has an analysts' consensus of $140.57 which suggests that it could grow by 5.23%. Given that West Pharmaceutical Services has higher upside potential than Abbott Laboratories, analysts believe West Pharmaceutical Services is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 1 0 ABTAbbott Laboratories12 9 0 -
Is WST or ABT More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.647%.
-
Which is a Better Dividend Stock WST or ABT?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Abbott Laboratories offers a yield of 1.71% to investors and pays a quarterly dividend of $0.59 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or ABT?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. West Pharmaceutical Services's net income of $89.8M is lower than Abbott Laboratories's net income of $1.3B. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.10x while Abbott Laboratories's PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.34x versus 5.51x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.34x 33.10x $698M $89.8M ABTAbbott Laboratories5.51x 17.33x $10.4B $1.3B
-
Which has Higher Returns WST or PDEX?
Pro-Dex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 18.81%. West Pharmaceutical Services's return on equity of 17.47% beat Pro-Dex's return on equity of 29.31%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B PDEXPro-Dex33.3% $0.98 $53.6M -
What do Analysts Say About WST or PDEX?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 33.71%. On the other hand Pro-Dex has an analysts' consensus of $56.00 which suggests that it could grow by 38.68%. Given that Pro-Dex has higher upside potential than West Pharmaceutical Services, analysts believe Pro-Dex is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 1 0 PDEXPro-Dex1 0 0 -
Is WST or PDEX More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.171, suggesting its less volatile than the S&P 500 by 82.891%.
-
Which is a Better Dividend Stock WST or PDEX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PDEX?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Pro-Dex quarterly revenues of $17.4M. West Pharmaceutical Services's net income of $89.8M is higher than Pro-Dex's net income of $3.3M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.10x while Pro-Dex's PE ratio is 14.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.34x versus 2.12x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.34x 33.10x $698M $89.8M PDEXPro-Dex2.12x 14.47x $17.4M $3.3M
-
Which has Higher Returns WST or TFX?
Teleflex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 13.56%. West Pharmaceutical Services's return on equity of 17.47% beat Teleflex's return on equity of 3.41%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B TFXTeleflex55.58% $2.07 $6B -
What do Analysts Say About WST or TFX?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 33.71%. On the other hand Teleflex has an analysts' consensus of $157.62 which suggests that it could grow by 28.91%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 1 0 TFXTeleflex0 11 0 -
Is WST or TFX More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Teleflex has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.761%.
-
Which is a Better Dividend Stock WST or TFX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Teleflex offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TFX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Teleflex quarterly revenues of $700.7M. West Pharmaceutical Services's net income of $89.8M is lower than Teleflex's net income of $95M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.10x while Teleflex's PE ratio is 38.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.34x versus 1.90x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.34x 33.10x $698M $89.8M TFXTeleflex1.90x 38.57x $700.7M $95M
-
Which has Higher Returns WST or TMCI?
Treace Medical Concepts has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of -30.29%. West Pharmaceutical Services's return on equity of 17.47% beat Treace Medical Concepts's return on equity of -47.17%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B TMCITreace Medical Concepts79.69% -$0.25 $158.8M -
What do Analysts Say About WST or TMCI?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 33.71%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 69.49%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 1 0 TMCITreace Medical Concepts2 5 0 -
Is WST or TMCI More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WST or TMCI?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TMCI?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. West Pharmaceutical Services's net income of $89.8M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.10x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.34x versus 1.70x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.34x 33.10x $698M $89.8M TMCITreace Medical Concepts1.70x -- $52.6M -$15.9M
-
Which has Higher Returns WST or UFPT?
UFP Technologies has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 11.6%. West Pharmaceutical Services's return on equity of 17.47% beat UFP Technologies's return on equity of 19.38%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B UFPTUFP Technologies28.45% $2.21 $543.4M -
What do Analysts Say About WST or UFPT?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 33.71%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 32.79%. Given that West Pharmaceutical Services has higher upside potential than UFP Technologies, analysts believe West Pharmaceutical Services is more attractive than UFP Technologies.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 1 0 UFPTUFP Technologies1 2 0 -
Is WST or UFPT More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.118, suggesting its more volatile than the S&P 500 by 11.848%.
-
Which is a Better Dividend Stock WST or UFPT?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or UFPT?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than UFP Technologies quarterly revenues of $148.1M. West Pharmaceutical Services's net income of $89.8M is higher than UFP Technologies's net income of $17.2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.10x while UFP Technologies's PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.34x versus 3.33x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.34x 33.10x $698M $89.8M UFPTUFP Technologies3.33x 28.67x $148.1M $17.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is down 0.53% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 8.78% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 1.63% over the past day.
